BI Asset Management Fondsmaeglerselskab A S Purchases 13,988 Shares of United Therapeutics Co. (NASDAQ:UTHR)

BI Asset Management Fondsmaeglerselskab A S grew its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 360.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,865 shares of the biotechnology company's stock after purchasing an additional 13,988 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in United Therapeutics were worth $3,928,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Cambridge Investment Research Advisors Inc. raised its position in United Therapeutics by 9.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 141 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of United Therapeutics by 48.8% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 2,345 shares of the biotechnology company's stock valued at $530,000 after purchasing an additional 769 shares in the last quarter. TD Asset Management Inc lifted its position in shares of United Therapeutics by 111.5% in the 3rd quarter. TD Asset Management Inc now owns 7,112 shares of the biotechnology company's stock worth $1,606,000 after purchasing an additional 3,750 shares during the period. Fifth Third Bancorp boosted its stake in shares of United Therapeutics by 10.7% during the third quarter. Fifth Third Bancorp now owns 1,803 shares of the biotechnology company's stock valued at $407,000 after purchasing an additional 175 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in United Therapeutics by 2.9% during the third quarter. Teacher Retirement System of Texas now owns 12,400 shares of the biotechnology company's stock valued at $2,801,000 after buying an additional 347 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price target on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Oppenheimer boosted their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an "outperform" rating in a research note on Thursday, May 2nd. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday. SVB Leerink initiated coverage on United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 price target on the stock. Finally, The Goldman Sachs Group raised their price objective on United Therapeutics from $218.00 to $240.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of "Buy" and an average target price of $308.78.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded up $0.41 on Monday, reaching $274.67. 333,292 shares of the stock were exchanged, compared to its average volume of 460,013. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $275.42. The business has a 50 day moving average price of $244.01 and a two-hundred day moving average price of $232.40. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $12.18 billion, a price-to-earnings ratio of 12.90 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. During the same period in the prior year, the firm earned $4.86 EPS. The business's revenue for the quarter was up 33.7% on a year-over-year basis. Analysts anticipate that United Therapeutics Co. will post 24.2 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company's stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $236.45, for a total value of $1,418,700.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $8,680,079.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company's stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $236.45, for a total value of $1,418,700.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at $8,680,079.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christopher Patusky sold 1,680 shares of the firm's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the sale, the director now owns 4 shares in the company, valued at $896. The disclosure for this sale can be found here. Over the last three months, insiders have sold 153,740 shares of company stock valued at $37,031,694. 12.50% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.